Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Original communication

Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis

Published Online:January 22, 2019https://doi.org/10.1024/0301-1526/a000774

Abstract

Summary.Background: The optimal duration of anticoagulation therapy (AT) following catheter-based therapy of acute iliofemoral deep vein thrombosis (IFDVT) with stent placement is unknown. Theoretically, resolving the underlying obstructive iliac vein lesion by a stent may eliminate the main trigger for recurrence, the post-thrombotic syndrome (PTS), and the need for extended-duration AT. Patients and methods: From 113 patients with acute IFDVT who underwent endovascular thrombus removal and stent placement, we compared patency rates and clinical outcomes between 58 patients on limited-duration AT (3–12 month) and 55 patients on extended-duration AT (> 12 months). Results: Mean follow-up duration was 26 ± 18 (range 3–77) months; it was 24 ± 18 (range 3–69) months after cessation of AT in the limited-duration AT group. In comparison to patients with extended-duration AT, patients with limited-duration AT were younger (38 versus 54 years; p < 0.001), more often female (74 % versus 49 %; p = 0.01), and had less often prior venous thromboembolism (VTE) (9 % versus 35 %; p = 0.001). May-Thurner syndrome was more frequent in the limited-duration AT group (66 % versus 38 %; p = 0.004). Overall, primary and secondary patency rates at 24 months were 80 % (95 % CI, 70–87 %) and 95 % (95 % CI, 88–98 %), respectively, with no difference between the groups. Overall, 17 (15 %) patients developed recurrent VTE, of which 14 (82 %) events were thrombotic stent occlusions, and 13 (76 %) events occurred during AT. In the limited-duration AT group, 98 % patients were free from the PTS at two years with a VTE recurrence rate of 3.5 per 100 patient years after cessation of AT. Conclusions: In selected patients with acute IFDVT and patent venous stent, particularly in younger and otherwise healthy patients with May-Thurner syndrome, it appears to be safe to discontinue AT 3–12 months after endovascular treatment. Clinical Trial Registration: The study is registered on the National Institutes of Health website (ClinicalTrials.gov; identifier NCT02433054).

References

  • 1 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46. First citation in articleCrossref Medline, Google Scholar

  • 2 Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med. 2001;110(7):515–9. First citation in articleCrossref Medline, Google Scholar

  • 3 Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. The clinical course of deep-vein thrombosis Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4):423–8. First citation in articleMedline, Google Scholar

  • 4 Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013;11(5):795–805. First citation in articleCrossref Medline, Google Scholar

  • 5 Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE, Jr. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg. 1993;18(4):596–605; discussion 6–8. First citation in articleCrossref Medline, Google Scholar

  • 6 Haig Y, Enden T, Slagsvold CE, Sandvik L, Sandset PM, Klow NE. Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2014;2(2):123–130. First citation in articleCrossref Medline, Google Scholar

  • 7 Sillesen H, Just S, Jorgensen M, Baekgaard N. Catheter directed thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. Eur J Vasc Endovasc Surg. 2005;30(5):556–562. First citation in articleCrossref Medline, Google Scholar

  • 8 Chung JW, Yoon CJ, Jung SI, Kim HC, Lee W, Kim YI, et al. Acute iliofemoral deep vein thrombosis: evaluation of underlying anatomic abnormalities by spiral CT venography. J Vasc Interv Radiol. 2004;15(3):249–256. First citation in articleCrossref Medline, Google Scholar

  • 9 Birn J, Vedantham S. May-Thurner syndrome and other obstructive iliac vein lesions: meaning, myth, and mystery. Vasc Med. 2015;20(1):74–83. First citation in articleCrossref Medline, Google Scholar

  • 10 Engelberger RP, Fahrni J, Willenberg T, Baumann F, Spirk D, Diehm N, et al. Fixed low-dose ultrasound-assisted catheter-directed thrombolysis followed by routine stenting of residual stenosis for acute ilio-femoral deep-vein thrombosis. Thromb Haemost. 2014;111(6):1153–1160. First citation in articleCrossref Medline, Google Scholar

  • 11 Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA. 2015;314(1):31–40. First citation in articleCrossref Medline, Google Scholar

  • 12 Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2012;10(4):698–702. First citation in articleCrossref Medline, Google Scholar

  • 13 Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J.. 2017. doi: 10.1093/eurheartj/ehx003. PMID: 28329262 First citation in articleCrossref Medline, Google Scholar

  • 14 Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. CHEST. 2016;149(2):315–352. First citation in articleCrossref Medline, Google Scholar

  • 15 Meissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012;55(5):1449–1462. First citation in articleCrossref Medline, Google Scholar

  • 16 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg.. 2018. First citation in articleCrossref Medline, Google Scholar

  • 17 Dopheide JF, Sebastian T, Engelberger RP, Haine A, Kucher N. Early clinical outcomes of a novel rheolytic directional thrombectomy technique for patients with iliofemoral deep vein thrombosis. Vasa. 2018;47(1):56–62. First citation in articleLink, Google Scholar

  • 18 Villalta SBP, Piccioli A, Lensing AW, Prins MH, Prandoni P.. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome (abstract). Haemostasis. 1994;24 158a. First citation in articleGoogle Scholar

  • 19 Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010;52(5):1387–1396. First citation in articleCrossref Medline, Google Scholar

  • 20 Engelberger RP, Stuck A, Spirk D, Willenberg T, Haine A, Periard D, et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized-controlled trial. J Thromb Haemost. 2017;15(7):1351–1360. First citation in articleCrossref Medline, Google Scholar

  • 21 Vedantham S, Grassi CJ, Ferral H, Patel NH, Thorpe PE, Antonacci VP, et al. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. J Vasc Interv Radiol. 2009;20(7 Suppl): S391–S408. First citation in articleCrossref Medline, Google Scholar

  • 22 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694. First citation in articleCrossref Medline, Google Scholar

  • 23 Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149(10):698–707. First citation in articleCrossref Medline, Google Scholar

  • 24 Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017;377(23):2240–2252. First citation in articleCrossref Medline, Google Scholar

  • 25 Enden T, Haig Y, Klow NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31–38. First citation in articleCrossref Medline, Google Scholar

  • 26 Sharifi M, Bay C, Mehdipour M, Sharifi J, Investigators T. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. J Endovasc Ther. 2012;19(2):273–280. First citation in articleCrossref Medline, Google Scholar

  • 27 Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–1830. First citation in articleCrossref Medline, Google Scholar

  • 28 Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–e496S. First citation in articleCrossref Medline, Google Scholar

  • 29 Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(45):3145–3146. First citation in articleMedline, Google Scholar

  • 30 Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. First citation in articleCrossref Medline, Google Scholar

  • 31 Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. New Engl J Med. 2013;368(8):709–718. First citation in articleCrossref Medline, Google Scholar

  • 32 Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. First citation in articleCrossref Medline, Google Scholar

  • 33 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578–589. First citation in articleCrossref Medline, Google Scholar

  • 34 HtC Pieter Eijgenraam, ten Cate-Hoek Arina J. Venous stenting after deep venous thrombosis and antithrombotic therapy: A systematic review. Rev Vasc Med. 2014;2:88–97. First citation in articleCrossref, Google Scholar

  • 35 Jeraj L, Jezovnik MK, Poredos P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thrombosis Research. 2017;157:46–48. First citation in articleCrossref Medline, Google Scholar

  • 36 Coleman CI, Beyer-Westendorf J, Bunz TJ, Mahan CE, Spyropoulos AC. Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. Clin Appl Thromb-Hem. 2018;24(4):575–582. First citation in articleCrossref Medline, Google Scholar